Imodium Multi-symptom Relief is a drug owned by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 17, 2017. Details of Imodium Multi-symptom Relief's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6103260 | Simethicone/anhydrous calcium phosphate compositions |
Jul, 2017
(7 years ago) |
Expired
|
| US5679376 | Simethicone containing pharmaceutical compositions |
Oct, 2014
(10 years ago) |
Expired
|
| US5489436 | Taste mask coatings for preparation of chewable pharmaceutical tablets |
Feb, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Imodium Multi-symptom Relief is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Imodium Multi-symptom Relief's family patents as well as insights into ongoing legal events on those patents.
Imodium Multi-symptom Relief's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Imodium Multi-symptom Relief's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 17, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Imodium Multi-symptom Relief Generic API suppliers:
Loperamide Hydrochloride; Simethicone is the generic name for the brand Imodium Multi-symptom Relief. 8 different companies have already filed for the generic of Imodium Multi-symptom Relief, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Imodium Multi-symptom Relief's generic
How can I launch a generic of Imodium Multi-symptom Relief before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Imodium Multi-symptom Relief's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Imodium Multi-symptom Relief's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Imodium Multi-symptom Relief -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2 mg/125 mg | |||||
| 2 mg/125 mg | 29 Dec, 2004 |
About Imodium Multi-symptom Relief
Imodium Multi-Symptom Relief is a drug owned by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div. Imodium Multi-Symptom Relief uses Loperamide Hydrochloride; Simethicone as an active ingredient. Imodium Multi-Symptom Relief was launched by J And J Consumer Inc in 2000.
Approval Date:
Imodium Multi-symptom Relief was approved by FDA for market use on 30 November, 2000.
Active Ingredient:
Imodium Multi-symptom Relief uses Loperamide Hydrochloride; Simethicone as the active ingredient. Check out other Drugs and Companies using Loperamide Hydrochloride; Simethicone ingredient
Dosage:
Imodium Multi-symptom Relief is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG;125MG | TABLET, CHEWABLE | Discontinued | ORAL |